Abstract:Ryanodine receptor type 2 (RyR-2) mediates Ca(2+) release from sarcoplasmic reticulum and contributes to myocardial contractile function. However, the role of RyR-2 in the development of cardiac hypertrophy is not completely understood. Here, mice with or without reduction of RyR-2 gene (RyR-2(+/-) and wild-type, respectively) were analyzed. At baseline, there was no difference in morphology of cardiomyocyte and heart and cardiac contractility between RyR-2(+/-) and wild-type mice, although Ca(2+) release from sarcoplasmic reticulum was impaired in isolated RyR-2(+/-) cardiomyocytes. During a 3-week period of pressure overload, which was induced by constriction of transverse aorta, isolated RyR-2(+/-) cardiomyocytes displayed more reduction of Ca(2+) transient amplitude, rate of an increase in intracellular Ca(2+) concentration during systole, and percentile of fractional shortening, and hearts of RyR-2(+/-) mice displayed less compensated hypertrophy, fibrosis, and contractility; more apoptosis with less autophagy of cardiomyocytes; and similar decrease of angiogenesis as compared with wild-type ones. Moreover, constriction of transverse aorta-induced increases in the activation of calcineurin, extracellular signal-regulated protein kinases, and protein kinase B/Akt but not that of Ca(2+)/calmodulin-dependent protein kinase II, and its downstream targets in the heart of wild-type mice were abolished in the RyR-2(+/-) one, suggesting that RyR-2 is a regulator of calcineurin, extracellular signal-regulated protein kinases, and Akt but not of calmodulin-dependent protein kinase II activation during pressure overload. Taken together, our data indicate that RyR-2 contributes to the development of cardiac hypertrophy and adaptation of cardiac function during pressure overload through regulation of the sarcoplasmic reticulum Ca(2+) release; activation of calcineurin, extracellular signal-regulated protein kinases, and Akt; and cardiomyocyte survival. (Hypertension. 2011;58:1099-1110.).

RyR2 Stabilizer Attenuates Cardiac Hypertrophy by Downregulating TNF-α/NF-κB/NLRP3 Signaling Pathway through Inhibiting Calcineurin

Regulation of Phospholamban and Sarcoplasmic Reticulum Ca2+-ATPase by Atorvastatin: Implication for Cardiac Hypertrophy

RyR2-targeting therapy prevents left ventricular remodeling and ventricular tachycardia in post-infarction heart failure

Chronic Dantrolene Treatment Attenuates Cardiac Dysfunction and Reduces Atrial Fibrillation Inducibility in a Rat Myocardial Infarction Heart Failure Model

Abstract 3768: the Deficiency of Ryanodine Receptor Type 2 Accelerates Transition from Adaptive Cardiac Hypertrophy to Dysfunction During Pressure Overload

Ryanodine receptor type 2 is required for the development of pressure overload-induced cardiac hypertrophy.

Dantrolene: effects on abnormal intracellular Ca2+ handling and inotropy in postinfarcted rat myocardium

Inhibition of dystrophin breakdown and endothelial nitric-oxide synthase uncoupling accounts for cytoprotection by 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e) in left ventricular hypertrophied Mice.

Abstract 16920: Permanent Reduction of Ryr2 Improves Lv Ejection Fraction in Heart Failure

Ryanodine Receptor Type 2 Plays a Role in the Development of Cardiac Fibrosis under Mechanical Stretch Through TGFβ-1.

Essential Role of Calmodulin in RyR Inhibition by Dantrolene

Ryanodine Receptor Stabilization Therapy Suppresses Ca 2+ -Based Arrhythmias in a Novel Model of Metabolic HFpEF

Ryanodine receptor inhibitor dantrolene reduces hypoxic-ischemic brain injury in neonatal mice

Ryanodine Receptor Stabilization Therapy Suppresses Ca -Based Arrhythmias in a Novel Model of Metabolic HFpEF

Targeted expression of receptor-associated late transducer inhibits maladaptive hypertrophy via blocking epidermal growth factor receptor signaling.

Calcineurin Inhibitor Attenuates the Development and Induces the Regression of Cardiac Hypertrophy in Rats with Salt-Sensitive Hypertension.

Mineralocorticoid Modulation of Cardiac Ryanodine Receptor Activity is Associated with Downregulation of FK506-binding Proteins.

Stabilizing Ryanodine Receptor Type 2: A Novel Strategy for the Treatment of Atrial Fibrillation

Reduced Expression of Cardiac Ryanodine Receptor Protects Against Stress-Induced Ventricular Tachyarrhythmia, but Increases the Susceptibility to Cardiac Alternans.

The Ryanodine Receptor Stabilizer S107 Ameliorates Contractility of Adult Rbm20 Knockout Rat Cardiomyocytes

Ca2+/Calmodulin-Dependent Protein Kinase II Regulation by Inhibitor of RIPK3 Protects Against Cardiac Hypertrophy